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Dietary intervention
Muscle ﬁbers typeDietary fat restriction and increased carbohydrate intake are part of treatment in very-long-chain acyl-CoA
dehydrogenase (VLCAD)-deﬁciency, the most common defect of long-chain fatty acid oxidation. The
long-term impact of these interventions is unknown. We characterized here the effects of a fat-reduced,
carbohydrate-enriched diet and an increased fat intake on energy metabolism in a mouse model of
VLCAD-deﬁciency.
Wild-type and VLCAD−/−mice were fed one year either with a normal (5.1%), a high fat (10.6%) or a low-fat,
carbohydrate-enriched (2.6%) diet. Dietary effects on genes involved in lipogenesis, energy homeostasis and
substrate selection were quantiﬁed by real-time-PCR. Acylcarnitines as sign of impaired energy production
were determined in dried blood spots and tissues. White skeletal muscle was analyzed for muscle ﬁber
type as well as for glycogen and triglyceride content.
Both dietary modiﬁcations induced enhanced triacylglyceride accumulation in skeletal muscle and inhibition
of glucose oxidation. This was accompanied by an up-regulation of genes coding for oxidative muscle ﬁber
type I and a marked accumulation of acylcarnitines, especially prominent in the heart (164±2.8 in
VLCAD−/− vs. 82.3±2.1 in WT μmol/mg) under a low-fat, carbohydrate-enriched diet.
We demonstrate here that both dietary interventions with respect to the fat content of the diet reverse en-
dogenous compensatory mechanisms in muscle that have evolved in VLCAD−/− mice resulting in pro-
nounced energy deﬁciency. In particular, the low-fat carbohydrate-enriched diet was not effective in the
long term. Further experiments are necessary to deﬁne the optimal energy provision for fatty acid oxidation
defects.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The very-long-chain acyl-CoAdehydrogenase (VLCAD) catalyzes the
ﬁrst of four sequential reactions in the mitochondrial β-oxidation of
long-chain fatty acids. Deﬁciency of VLCAD (OMIM 201475) is an
inherited autosomal recessive disorder with an incidence of 1:50,000
to 1:100,000 [1–3]. Catabolic situations in which fatty acids become
the predominant source of energy may result in life-threatening events
due to energy deﬁciency as reﬂected by severe acylcarnitine accumula-
tion. The clinical phenotype displays great heterogeneity [4,5] and typ-
ical symptoms often appear after prolonged fasting or as a consequence
of infectious illnesses. Forms of presentation comprise cardiomyopathy,
hypoketotic hypoglycemia, Reye-like symptoms and rhabdomyolysis
[6,7].iatrics, Center for Pediatrics and
se 1, 79106 Freiburg, Germany.
Tucci).
rights reserved.The implementation of newborn screening for VLCAD-deﬁciency
in many countries worldwide allows the recognition of an increasing
number of patients who can be treated immediately after birth to pre-
vent severe metabolic derangement [3]. Besides the avoidance of
fasting treatment recommendations also include dietary interventions
such as fat restriction and fat modiﬁcation by replacement of the nor-
mal long-chain triacylglycerides with medium-chain triacylglycerides
(MCT) [8]. The application of odd-number medium-chain fatty acids
because of their anaplerotic character has also been described to be ef-
fective [9]. However, in asymptomatic patients identiﬁed by newborn
screening the application of dietary interventions is widely debated.
Observations in patients presenting with the muscular phenotype re-
vealed that the administration of an MCT bolus immediately prior to
exercise resulted in great beneﬁcial effects [10], whereas in VLCAD-
deﬁcient (VLCAD−/−) mice long-term supplementation with an
MCT-based diet led to a strong enhancement of visceral and hepatic
lipid accumulation [11]. Concomitant studies with changes in the
dietary fat content also performed in VLCAD−/− mice supplied over
ﬁve weeks demonstrated no positive effects on exercising capacity
[12,13].
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are currently recommended in the life-long. Therefore, the study of
long-term effects is of great clinical relevance. In addition, there is seri-
ous concern that an increased fat intake, especially over longer time pe-
riods, may result in severe metabolic decompensation and signiﬁcant
fat accumulation.
The VLCAD−/−mouse is an excellentmodel to study the effect of di-
etary intervention as thesemice display a phenotype very similar to the
human VLCADD [2]. Indeed, although asymptomatic under resting con-
ditions, VLCAD−/− mice present with hypoglycemia, hepatopathy and
skeletal myopathy during situations of increased energy demand
[14,15].
To address the question how the dietary fat and carbohydrate
content inﬂuences lipid metabolism and energy homeostasis in the
long-term, we fed wild-type (WT) and VLCAD−/− mice over one
year with a low-fat, carbohydrate-enriched diet and compared the
effects with mice fed a high-fat diet and a normal diet. In blood, lipo-
proteins, triacylglycerides (TAG) and ketone bodies were measured.
In addition, hepatic lipid accumulation as well as hepatic and muscu-
lar glycogen content was quantiﬁed. The effects of different dietary fat
content on the expression of genes involved in hepatic lipogenesis
were analyzed by real-time-PCR. In heart and white skeletal muscle
the expression of genes regulating energy homeostasis and substrate
selection was quantiﬁed. Moreover, in skeletal muscle the expression
of different muscle ﬁber types using different substrates for energy
production was determined in response to the applied diets. Finally,
acylcarnitines as marker for impaired energy production from fatty
acid oxidation were measured in dried blood spots (DBS), liver,
heart and skeletal muscle.
2. Materials and methods
2.1. Animals
Experiments were performed on fourth- to ﬁfth-generation inter-
crosses of C57BL6+129sv VLCAD genotypes [14]. Littermates served
as controls and genotyping of mice was performed as described by
Exil et al. [14]. Groups consisting of 5–6 mice of both sexes (50:50),
one year old, were investigated under well-fed, non-fasting condi-
tions. Mice were sacriﬁced by CO2 asphyxiation. Liver, heart and
white skeletal muscle (gastrocnemius muscle) were rapidly removed
and immediately frozen in liquid nitrogen.
All animal studies were performed with the approval of the
Heinrich-Heine-University Institutional Animal Care and Use Com-
mittee and in accordance with the Committees' (LANUV) guidelines.
2.2. Diet composition
Animals were divided into three groups consisting of WT and
VLCAD−/− mice, each receiving a diet with a different amount of fat.
After being weaned, the ﬁrst group received a regular puriﬁed
mouse diet containing 5.1% crude fat (ssniff® EF R/M Control, ssniff
Spezialdiäten GmbH), corresponding to 12% of metabolizable energy
from fat calculated with Atwater factors. The second group received
a diet containing 10.6% crude fat (ssniff® EF R/M Control, ssniff
Spezialdiäten GmbH), corresponding to 24% of metabolizable energy
from fat calculated with Atwater factors. This diet is subsequently re-
ferred to as fat-enriched diet (FAT; Supplemental Table 1). In this diet
the starch content was reduced up to 45.6% to meet the increased fat
content. The third group received a diet referred to as low-fat diet
(CHO) containing 2.6% crude fat (ssniff® EF R/M control, ssniff
GmbH), corresponding to 7% of metabolizable energy from fat calcu-
lated with Atwater factors. In this diet the fat was replaced by starch
representing together 53% of the crude nutrients (Supplemental
Table 1). All diets were based on puriﬁed feed ingredients and
contained the same concentration of all other nutrients as follows:94.8% dry matter, 17.8% crude protein (N×6.25), 5% crude ﬁber, 5.3%
crude ash, 61.9% nitrogen free extract, 14.8% dextrin and 11% sugar.
2.3. Analysis of TAG, free fatty acids (FFA) lipoproteins and ketone bodies
Serumwas collected 90 min from the last meal. The concentration
of FFA, lipoproteins, ketone bodies as well as blood and hepatic TAG
were measured as duplicates using commercially available enzymatic
kits (EnzyChrom, FFA Assay Kit; EnzyChrom HDL and VLDL/LDL Assay
Kit; EnzyChrom Ketone bodies Assay Kit, EnzyChrom Triglyceride
Assay Kit, BioTrend Cologne, Germany) on an Inﬁnite M200 Tecan
(Crailsheim, Germany) plate reader. All assays were performed fol-
lowing the manufacturer's instructions.
2.4. Intrahepatic lipid content
The intrahepatic lipid content was measured gravimetrically
according to a method by Folch [16] modiﬁed as previously reported
[17].
2.5. Analysis of acylcarnitines
Analysis of long-chain acylcarnitines was performed as previously
described [18]. Brieﬂy, acylcarnitines were extracted from dried blood
spots and tissues with acetonitrile/water (80/20% v/v) in the presence
of [2H3] free carnitine, [2H3] octanoyl-carnitine and [2H3] palmitoyl-
carnitine as internal standard. The extracted supernatant was dried
and the butylated acylcarnitines were analyzed by electron spray
ionization tandem mass spectrometry (ESI-MS/MS). All even-chain
C4–C18 acylcarnitines (saturated and unsaturated) were measured.
2.6. Glycogen content and pyruvate kinase (PK) activity
Glycogen concentrations in muscle and liver samples were mea-
sured as duplicates using an enzymatic kit (EnzyChrom™ Glycogen
Assay Kit, BioTrend, Cologne) on an Inﬁnite M200 Tecan (Crailsheim,
Germany) plate reader. The assays were performed following the
manufacturer's instructions. PK was measured with the Pyruvate
Kinase Assay Kit as recommended by the manufacturer (BioVision,
Mountain View, USA).
2.7. Real-time-PCR analysis
Total RNA was isolated from liver, heart and white skeletal muscle
with the RNeasy mini kit (Qiagen, Hilden Germany). Forward and
reverse primers for β-actin (BC138614), stearoyl element binding
protein-1c (SREBP-1c; NM_01148), fatty acid synthase (FASN;
NM_007988), acetyl-CoA carboxylase 1α (ACC1α; NM_133360),
diacylglycerol O-acyltransferase 2 (DGAT2; NM_026384), peroxisome
proliferative activated receptor gamma coactivator 1 alpha (PGC1a;
BC066868), pyruvate dehydrogenase kinase isoenzyme 4 (PDK4;
NM_013743), skeletal muscle α1 actin (Acta1; NM_009606), tropo-
nin I skeletal, slow 1 (Tnni1; NM_021467), troponin I, skeletal, fast 2
(Tnni2; NM_009405), troponin C, cardiac/slow skeletal (Tnnc1;
NM_009393), troponin C2, fast (Tnnc2; NM_009394), troponin T1,
skeletal, slow (Tnnt1; BC141142), myosin heavy chain α (MHCα;
NM_001164171) and myosin heavy chain β (MHCβ; NM_080728)
were designed with the FastPCR program (R. Kalendar, Institute of
Biotechnology, Helsinki). Gene function and primer sequences are
reported in Supplemental Table 2. Real Time PCR was performed in
a single step procedure with the QuantiTect SYBR Green™ RT-PCR
(Qiagen, Hilden, Germany) on an Applied Biosystems 7500 Real-
Time PCR System in Micro Amp 96-well optical reaction plates
capped with MicroAmp optical caps (Applied Biosystems, Foster
City, CA, USA) as previously described [19]. The values in all samples
Table 1
Clinical phenotype and serum lipids.
Control FAT CHO
WT VLCAD−/− WT VLCAD−/− WT VLCAD−/−
Body weight [g] 29.9±2.3 32.2±2.6 36.6±3.3# 32.6±1.6 31.2±1.6 27.7±1#
Ratio liver/body weight [mg/g] 4.2±0.3 4.5±0.1 4±0.2 4.2±0.2 4.5±0.2 5±0.3#
Cholesterol total [mg/dL] 83.6±2.4 109.4±9.4 100.4±5.5 124.7±10.2 114.2±8.9 124.8±12.9
HDL [mg/dL] 54.7±8.6 47.5±12.6 102.5±10.5# 105.9±7# 80.7±9.2 91.5±10.1#
VLDL/LDL [mg/dL] 18.1±3.5 23.2±1.8 30.4±2.1# 29.4±2.1# 22.9±2.1 24.8±3.2
Serum TAG [mg/dL] 46.6±1.7 88.51±23.2* 38.9±5.6 71.3±12.2* 41.9±12.3 70.1±18.5
FFA [μM] 378.5±19.8 791.8±42.3* 310.2±33.5 776.3±37* 380.8±41.6 462.9±4.3*#
Ketone bodies [mM] 0.25±0.09 0.37±0.11* 0.96±0.13# 1.61±0.29*# 0.46±0.07# 1.03±0.16*#
Liver lipids [% of dry weight] 14±0.2 17.3±0.9 14±0.9 14.7±0.4 16.0±1.5 17.1±0.9
Values are represented as mean±SEM (n=5–6).* indicates signiﬁcant differences betweenWT and VLCAD−/−mice within a diet group. # indicates signiﬁcant differences between
either WT or VLCAD−/− mice under different dietary conditions as compared to the control diet. * and # values were considered signiﬁcant if pb0.05 (two way ANOVA and
Student's t-test).
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β-actin.
2.8. Statistical analysis
ESI-MS/MS data were acquired and analyzed using MassLynx NT
v4.0 (Micromass, UK). All data are presented as the mean±standard
error of the mean (SEM). Statistical analysis of differences between
two means was assessed by Student's t test. Multiple means were
compared by a two-way analysis of the variance (ANOVA) with a
Bonferroni post hoc test (GraphPad Prism 5.0, San Diego, CA, USA).
A probability level of pb0.05 was regarded as signiﬁcant.
3. Results
3.1. Clinical phenotype and serum lipids
As shown in Table 1, mean body weights were not signiﬁcantly dif-
ferent between both genotypes under the respective diets. However,
WT mice under a FAT diet displayed a signiﬁcantly higher mean body
weight as compared to WT mice under a normal diet (pb0.05).0
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The analysis of serum lipids revealed that a FAT diet led to signiﬁ-
cantly higher lipoproteins in both genotypes as compared to control
conditions (pb0.05), with the exception of total cholesterol (Table 1).
In contrast, mutants upon a CHO diet displayed an increment only in
HDL lipoprotein as compared to VLCAD−/− mice under a normal diet
(91.5±10.1 vs. 47.5±12.6 mg/dL; pb0.05). Similar to previously
reported data [17], the concentration of serum TAG in VLCAD−/−mice
under a control diet was two-fold higher as compared toWT littermates
(88.51±23.2 vs. 46.6±1.7 mg/dL; pb0.05). Variation of the dietary fat
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bodies as compared to WT mice under the same dietary regimen
(1.03±0.16 vs. 0.46±0.07 mM; pb0.05) and also as compared to
VLCAD−/−mice under a normal diet (pb0.05).
3.2. Hepatic and muscular lipid accumulation
WT and VLCAD−/− mice did not show substantial differences in
the total intrahepatic lipid levels under all three diets (Table 1),
whereas hepatic TAG were signiﬁcantly increased in VLCAD−/−
mice under both dietary fat content modiﬁcations as compared to
WT mice (Fig. 1A; pb0.05). Similar to the liver, both diets resulted
in a more than two-fold increased TAG accumulation in skeletal mus-
cle of VLCAD−/− mice as compared to WT littermates (Fig. 1B;
pb0.05).
3.3. Glycogen contributes to energy supply in VLCAD−/− mice fed a FAT
diet
In a situation of increased energy demand such as during physical
exercise, glucose and glycogen strongly contribute to the energy sup-
ply [20]. Because of defective FAO, already under well-fed resting
conditions VLCAD−/−mice need to recover the required energy by al-
ternative sources. Indeed, upon a normal diet (Fig. 1C) liver glycogen
was slightly reduced in VLCAD−/−mice (pb0.062). The FAT and CHO
diets resulted in enhanced glycogen storage in the mutants, however,
this was only signiﬁcant under a CHO diet (pb0.05). In muscle we ob-
served a completely different situation (Fig. 1D). In fact, VLCAD−/−
mice showed a marked decrease in glycogen stores under a FAT diet
as compared to their WT littermates (2.5±0.27 vs. 4±0.5 mg/g;
pb0.05). On the other hand, probably due to the high carbohydrate
content of the diet, the glycogen content in skeletal muscle of
VLCAD−/− mice was two-fold higher with a CHO diet as compared
to the normal diet (5.7±1.2 and 2.9±0.7 mg/g; pb0.05).
3.4. Effect of the diets on genes regulating lipogenesis, glucose
metabolism and muscle ﬁber type expression
3.4.1. Liver
To appoint whether modiﬁcation of the dietary fat content affects
hepatic lipogenesis in VLCAD−/− mice, we measured the expression
at mRNA level of genes involved this pathway. In particular, we tested
the expression of the transcription factor SREBP-1c, which regulates
lipid homeostasis, fatty acid biosynthesis and glucose metabolism
[21–24]. Moreover, the expression of FASN one of SREBP-1c target
genes, responsible for de novo and elongation of fatty acids and of
PGC1α and PDK4 regulating energy homeostasis and glucose oxida-
tion were tested as well.
In accordance to previous reports [11], weﬁnd in VLCAD−/−mice an
up-regulation of SREBP-1c and FASN indicative of an active lipogenesis
under a normal diet (Fig. 2A; pb0.05). Concomitantly, glucose oxidation
is suppressed as evidenced by the strong induction of PDK4 which
inhibits pyruvate dehydrogenase by phosphorylation (pb0.05). As
shown (Fig. 2B), a FAT diet further increased these effects with an
evenmore signiﬁcant up-regulation of SREBP-1c— also involved in cho-
lesterol and ketone body biosynthesis [25], and of FASN. In contrast to
previous data [13], lipogenesis was no longer up-regulated after one
year supplementation with a CHO diet (Fig. 2C). The signiﬁcant
up-regulation of the genes PGC1α and PDK4 under these conditions
was indicative of energy deﬁciency with a parallel inhibition of hepatic
glucose oxidation.
3.4.2. Heart
Because the heart is an organ with a high metabolic rate and with
a preference of fat as fuel we hypothesized signiﬁcant effects of
changes in the dietary macronutrient content on energy metabolism.Already under normal diet, there was marked evidence of energy de-
ﬁciency in VLCAD−/− mice, since PGC1α, PDK4 and Acta1, the last
being a marker for the reactivation of fetal gene program [40], were
strongly up-regulated (Fig. 3A; pb0.05). Interestingly, a fat overload
induced in VLCAD−/− mice similar results with the exception of
PDK4 expression which is down-regulated (pb0.05), suggesting that
in these mice energy deﬁciency is mostly compensated by enhanced
glucose oxidation as shown in Fig. 3B. In contrast, the reduction of di-
etary fat with a concomitant increase in carbohydrates appeared to
positively affect cardiac energy metabolism since no difference in
the expression pattern of the analyzed genes could be detected be-
tween VLCAD−/− mice and WT mice under CHO diet (Fig. 3C) indic-
ative of a tissue-speciﬁc response to different dietary fat content.
3.4.3. Skeletal muscle
Similar to the data observed in heart of VLCAD−/− mice, there is
also evidence for energy deﬁciency in white skeletal muscle under a
normal diet as demonstrated by the marked up-regulation of PGC1α
050
100
150
200
250
300
R
el
. e
xp
re
ss
io
n 
[%
]
0
100
200
300
400
500
600
R
el
. e
xp
re
ss
io
n 
[%
]
0
50
100
150
200
250
300
PGC1α PDK4 Acta1 MHCα MHCβ
R
el
. e
xp
re
ss
io
n 
[%
]
A
B
C
*
* *
*
*
*
*
*
*
PGC1α PDK4 Acta1 MHCα MHCβ
PGC1α PDK4 Acta1 MHCα MHCβ
Fig. 3. Dietary effects on the expression of genes involved in energy homeostasis and
substrate selection in the heart. A) Control diet; B) FAT, fat-enriched diet; and
C) CHO, low-fat diet. White bars and black bars represent WT and VLCAD−/− mice, re-
spectively. Relative expression of PGC1α, PDK4,MHCα,MHCβ and Acta1was performed
by RT-PCR analysis. Values are represented as mean±SEM (n=5–6) and are
expressed as % of untreated WT mice. * indicates signiﬁcant differences between WT
and VLCAD−/− mice within a diet group. * values were considered signiﬁcant if
pb0.05 (two way ANOVA and Student's t-test).
0
500
1000
1500
2000
2500
3000
3500
4000
4500
R
el
. e
xp
re
ss
io
n 
[%
]
0
200
400
600
800
1000
1200
1400
1600
1800
2000
R
el
. e
xp
re
ss
io
n 
[%
]
0
50
100
150
200
250
300
PGC1α PDK4 Tnni1 Tnni2 Tnnc1 Tnnc2 Tnnt1
R
el
. e
xp
re
ss
io
n 
[%
]
*
*
*
*
*
*
*
*
*
*
*
*
*
A
B
C
PGC1α PDK4 Tnni1 Tnni2 Tnnc1 Tnnc2 Tnnt1
PGC1α PDK4 Tnni1 Tnni2 Tnnc1 Tnnc2 Tnnt1
Fig. 4. Dietary effects on muscle ﬁber type and genes regulating energy metabolism in
skeletal muscle. A) Control diet; B) FAT, fat-enriched diet; and C) CHO, low-fat diet.
White bars and black bars represent WT and VLCAD−/−mice, respectively. Relative ex-
pression of PGC1α, PDK4, Tnni1, Tnni2, Tnnc1, Tnnc2 and Tnnt1 was performed by
RT-PCR analysis. Values are represented as mean±SEM (n=5–6) and are expressed
as % of WT mice. * indicates signiﬁcant differences between WT and VLCAD−/− mice
within a diet group. * values were considered signiﬁcant if pb0.05 (two way ANOVA
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muscle ﬁber types in response to metabolic changes [26], we mea-
sured how this result affected the expression of genes coding for
the three troponin proteins in the white skeletal muscle. We observed
a signiﬁcant down-regulation of Tnni1, Tnnc1 and Tnnt1, expressing
the slow and more oxidative muscular ﬁber type I as compared
to WT mice. In contrast, Tnni2 and Tnnc2 coding for glycolytic
ﬁbers were up-regulated indicating metabolic adaptation towards
glycolytic energy production (pb0.05) as compensation for a defec-
tive fatty acid oxidation machinery [30]. Of particular interest was
the ﬁnding that under both, FAT and CHO diets, VLCAD−/−mice dem-
onstrated a completely different expression pattern (Fig. 4A–B),
in which overload of fat or carbohydrates seemed to reverse the
compensatory switch with enhanced expression of glycolytic muscle
ﬁbers. In these mice, the expression of Tnni1, Tnnc1 and Tnnt1, was
signiﬁcantly induced (pb0.05), indicating that both diets predomi-
nantly support an oxidative muscular ﬁber type I and strongly trigger
the adaptation towards oxidative energy production. As shown inFig. 4A, especially upon a FAT diet, the expression of these genes
was 40-fold higher in VLCAD−/−mice as compared to their WT litter-
mates in which the high-fat diet did not trigger the expression of ox-
idative muscle ﬁbers (pb0.05).
3.5. A low-fat (CHO) and a high-fat (FAT) diet affect glucose metabolism
in skeletal muscle of VLCAD−/− mice
In order to further determine the role of glucose as substrate for
energy production, we quantiﬁed the activity of PK in white skeletal
muscle as important enzyme regulating the rate of glucose oxidation.
As shown in Fig. 5, VLCAD−/− mice already displayed a nearly
two-fold higher activity as compared to WT littermates (3.65±0.60
vs. 1.99±0.27 mU/mg; pb0.05) under a normal diet. In contrast,
both modiﬁcations of the dietary fat content led to a marked
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VLCAD−/− mice, respectively. Values are reported as mean±SEM (n=5–6) and
expressed as mU/mg. * indicates signiﬁcant differences between WT and VLCAD−/−
mice within a diet group. # indicates signiﬁcant differences between either WT or
VLCAD−/− mice under different dietary conditions as compared to control diet * and
# values were considered signiﬁcant if pb0.05 (two way ANOVA and Student's t-test).
514 S. Tucci et al. / Biochimica et Biophysica Acta 1832 (2013) 509–516reduction of PK activity (Fig. 5) indicative of a reduced glucose oxida-
tion. This effect was particularly striking in VLCAD−/− mice under a
low-fat CHO diet with a reduction up to 50% as compared to WT
mice under the same dietary regimen (pb0.05) and up to 57% as com-
pared to VLCAD−/− mice under control diet (pb0.05).
3.6. Acylcarnitines accumulation is more pronounced in mice fed a
low-fat (CHO) diet
As shown in Fig. 6A, under all dietary regimens VLCAD−/− mice
displayed a signiﬁcant accumulation of acylcarnitines in blood as
compared to WT mice (pb0.05). Surprisingly, a CHO diet led to a fur-
ther increase in acylcarnitine content in mutants as compared to0
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Fig. 6. Accumulation of long-chain acylcarnitines in blood and tissues under different dietary
D) skeletal muscle. White bars and black bars represent WT and VLCAD−/− mice, respective
acylcarnitines (C14–C18) expressed as μmol/L for the blood and μmol/mg for tissues. * indic
dicates signiﬁcant differences between either WT or VLCAD−/− mice under different dietar
pb0.05 (two way ANOVA and Student's t-test).control conditions (26.4±1.03 and 10±0.57 μmol/mg; pb0.05). In
liver and heart this effect was even more pronounced with a more
than two-fold increase in VLCAD−/− mice as compared to WT mice
(Fig. 6B–C; pb0.05). A slight increase was also observed in mutants
under a FAT diet, although signiﬁcant only in cardiac tissue. In skeletal
muscle the concentration of long-chain acylcarnitines in VLCAD−/−
mice under a normal diet was slightly lower than that observed in
their WT littermates (pb0.064). However, as shown in Fig. 6C, an
overload of dietary fat or carbohydrates led to a signiﬁcant increase
in acylcarnitines suggestive of a marked energy deﬁciency (pb0.05).
4. Discussion
Dietary interventions such as fat-restriction and carbohydrate
supplementation are part of treatment in VLCAD-deﬁcient patients
and are applied long-term. We here demonstrate that the modiﬁca-
tion of the dietary fat and carbohydrate content had tremendous ef-
fects on metabolism of white skeletal muscle. Whereas, VLCAD−/−
mice keep their muscular energetic balance by a compensatory
switch towards an increased expression of genes coding for glycolytic
muscle ﬁber types under normal dietary conditions, an increased fat
or carbohydrate intake reverses these compensatory mechanisms
resulting in signiﬁcant muscular energy deﬁciency.
4.1. High fat diet
In VLCAD−/− patients an increased fat intake is especially avoided
because of expected accumulation of fat and fatty acid metabolites
and subsequent metabolic decompensation. Our data here show
that after one year supplementation with a high-fat diet VLCAD−/−
mice neither gain body weight nor display a signiﬁcant increase in
blood FFA and TAG, although the concentration of these metabolites
was markedly higher in mutants. Serum lipoproteins were strongly
increased in contrast to hepatic TAG indicating that the absorbed di-
etary lipids were further processed and secreted by the liver rather0
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ly. Values are reported as mean±SEM (n=5–6) and represent the sum of long-chain
ates signiﬁcant differences between WT and VLCAD−/−mice within a diet group. # in-
y conditions as compared to control diet * and # values were considered signiﬁcant if
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of SREBP-1c as demonstrated in this study and already previously
reported [11]. Consistent with the high expression of this transcrip-
tion factor, master regulator of cholesterol metabolism and ketone
body biosynthesis [27,28], was also the increased ketone body con-
centration in VLCAD−/−mice. Despite VLCAD ablation, the mitochon-
drial fatty acid oxidation of long-chain fatty acids in VLCAD−/− mice
is not completely disrupted since in contrast to humans mice highly
express the long-chain acyl-CoA dehydrogenase (LCAD), a mitochon-
drial enzyme as well, with overlapping substrate speciﬁcity to VLCAD
[29]. Although ubiquitously present in the organism, the contribution
of LCAD to energy supply in VLCAD−/−mice strongly differs between
the tissues [30]. Very recently it has been reported that especially in
the white skeletal muscle of VLCAD−/− mice the negligible LCAD ac-
tivity results in a marked energy deﬁciency with subsequent PGC1α-
induced up-regulation of glycolytic ﬁbers type II as also shown here
[26,31]. With respect to these data, the metabolic response of skeletal
muscle to fat overload is of great interest. After long-term supple-
mentation with a FAT diet we observed higher muscular TAG accu-
mulation without a parallel increase of muscular glycogen content.
This condition in association with an impaired fatty acid oxidation
as occurring in VLCAD−/− mice is known to play an important role
in the onset of muscular insulin resistance [32]. Indeed, intracellular
lipids initiate a phosphorylation cascade resulting in reduced activa-
tion of the Akt2 factor and a concomitant inhibition of GLUT4 translo-
cation to the plasma membrane and glucose uptake into the muscle
[33]. Although VLCAD−/− mice are protected against high-fat
diet-induced insulin resistance [34], this pathway additionally in-
duces morphological and metabolic changes by the promotion of
the oxidative muscular ﬁber type I [35–37]. The switch towards oxi-
dative muscle ﬁbers induced by modiﬁcation in dietary fat content
in VLCAD−/− mice, as already observed in the short-term [13,35] is
accompanied by a nearly 45% increase of long-chain acylcarnitine ac-
cumulation in skeletal muscle as compared to mutants under a nor-
mal diet indicative of a signiﬁcant metabolic decompensation and
energy deﬁciency [2,38].
Adaptation to a higher fat content in the long-term appeared also
in the heart. In fact, under the normal diet VLCAD−/−mice displayed
a strong up-regulation of genes typically expressed in developing
hearts and up-regulated in adult hearts in response to ametabolic car-
diac decompensation. Indeed, a developing heart in a relatively low
oxygen environment mostly uses glucose as energy source but after
birth with the exposure to a normal oxygen tension the carbohydrate
metabolism is rapidly replaced by fatty acid oxidation [39]. It has been
reported that in a situation of increased energy demand and functional
impairment the adult heart undergoes a shift in the energy substrate
metabolism returning to the fetal gene program [40]. One year supple-
mentation with a FAT diet slightly induced the fetal gene program
with glucose oxidation as the preferred energy producing pathway,
as shownby the very low expression of PDK4 in VLCAD−/−mice. Over-
all, cardiac energy deﬁciency was evidenced by the accumulation of
long-chain acylcarnitines under this dietary condition.
4.2. Low fat, carbohydrate-enriched diet
In clinical practice an important treatment recommendation
for mFAOD is the application of a fat-reduced diet [8]. A very
recent study in the VLCAD−/− mouse model showed that a low-fat,
carbohydrate-enriched diet strongly induced lipogenesis short term
[13]. After one year supplementation hepatic lipogenesis was no longer
active but the most striking ﬁnding was the increased muscular TAG
content comparable to that under high fat diet. As a consequence, we
observed in white skeletal muscle of VLCAD−/− mice a remarkable
up-regulation of oxidative ﬁber type I. We therefore speculate that
under this dietary condition the white skeletal muscle of VLCAD−/−
mice undergoes long-term a metabolic shift towards enhanced fattyacid oxidation evidenced by the strongly reduced PK activity as marker
for glucose oxidation and by the fact that the muscular glycogen stores
were not depleted. This resulted in a marked energy deﬁciency even in
situations, in which the balance between caloric intake and energy ex-
penditure may have been easily maintained. Indeed, we observed a
striking accumulation of long-chain acylcarnitines in skeletal muscle
of VLCAD−/− mice suggesting that here metabolic decompensation
was the result of chronic energy deﬁciency and not of increased energy
demand such as during physical exercise [2,13,41]. These ﬁndings are of
great importance since signiﬁcant accumulation of acylcarnitines in
blood and tissues have been reported in VLCAD−/− mice subjected to
fasting, cold or exercise stress, while under resting conditions the mu-
tants display much milder differences as compared to their WT litter-
mates [2,12,13,18,38]. Studies in humans demonstrated that dietary
interventions induce metabolic adaptation [42,43] and with regard to
the muscle this occurs with enhanced expression of oxidative ﬁber
type accompanied by reduced glucose oxidation [44]. Furthermore,
we may suspect that similar effects also appear in the heart whereas
the expression of muscular ﬁber markers was not tested. Indeed,
VLCAD−/− mice displayed an impressive accumulation of long-chain
C16–C18 acylcarnitines (Supplemental material), typical for this
mouse model [29] though the analysis of cardiac gene expression did
not reveal an up-regulation of the fetal gene program as usually occurs
during metabolic decompensation. These data would suggest that the
heart undergoes a substrate switch towards FAO as well; however, the
strong contribution of LCAD in this organ [30] allowsmaintaining ener-
getic balance under resting conditions.
Although obtained in a murine model, our results strongly correlate
with previous reported ﬁndings in humans on muscular metabolic ad-
aptations. On the basis of our results we hypothesize that a low-fat,
carbohydrate-enriched diet in the long-run does not represent a valid
solution in the treatment of VLCADD patients since despite the higher
carbohydrate content even under resting conditions the energy deﬁ-
ciency as demonstrated in VLCAD−/−mice was very pronounced.
4.3. Conclusions
Modiﬁcation of the dietary fat content represents an important in-
tervention in the treatment of VLCADD. Our data demonstrate how-
ever, that carbohydrate enrichment and long-chain fat reduction do
not meet the energetic demands in the long-term. Especially with re-
gard to white skeletal muscle, this dietary modiﬁcation resulted in an
enhanced expression of oxidative type I ﬁbers reversing compensato-
ry mechanisms that have evolved in muscle of VLCAD−/− mice. In
fact, these new adaptations signiﬁcantly worsened muscular energy
deﬁciency and future research has to determine which substrates
are optimal for energy production long-term.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.01.006.
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